• Current Status of Clinical Trials

CHA Medical Group, a prominent leader in stem cell research

Currently, CHA Medical Group clinical trials ongoing at domestic and overseas sites.

Product Indicationt Research Pre-Clinical PhaseⅠ PhaseⅡ PhaseⅢ Remarks
Pluripotent Stem Cell Based Pipeline
Embryonic Stem Cell derived Retinal Pigment
Epithelium Cell
(hESC-RPE)
Stargardt Macular
Degeneration (SMD)
Phase II in preparation
Age-related Macular
Degeneration (AMD)
Phase IIa ongoing
(4 Cohorts: 50,000/100,000
/150,000/200,000 cells)
Somatic Cell Nuclear Transfer derived Retinal Pigment Epithelium Cell (SCNT-RPE) Age-related Macular
Degeneration (AMD)
IIT(Investigator Initiated Trial) ongoing
Adult Stem Cell Based Pipeline
PLX-PAD
(Placenta derived Adherent Stromal Cell)
Intermittent
Claudication (IC)
Phase completed (Global clinical trial, 2018.04)
※ CHA Biotech & Pluristem Therapeutics
21 patients (Korea) 151 patients (Israel, US & EU)
172/172 patients treated
Critical Limb
Ischemia (CLI)
Phase III ongoing
246 patients (US and EU)
※ Pluristem Therapeutics
eCASs
(enhanced Umbilical Cord Adherent Stem Cell)
Stroke (ST) Phase I/IIa completed on April 24, 2017
(Korea’s first double-blind test)
19 out of 19 patients treated
(at Bundang CHA Medical Center)
Disk Degeneration (DD) Phase I/II a IND approved from MFDS
ePACs
(enhanced Placenta
derived Stem Cell)
Alzheimer's Disease (AD) Phase I/IIa IND approved from MFDS
4 out of 26 patients treated
Fetal NPC
(Neural Precursor Cell)
Parkinson’s Disease (PD) IIT ongoing
15 out of 15 patients treated
Adipocyte derived MSC
(Mesenchymal Stem Cell)
Disk Degeneration IIT completed in 2016
10 out of 10 patients treated
IIT IND approved from MFDS in 2017
Immune Cell Based Pipeline
Autologous Killer Cell
(CB-IC-01)
Recurrent Glioblastoma IIT (Investigator-Initiated Trial)